TISIDB

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Nucleus Cell junction
Domain	PF14603 Helically-extended SH3 domain PF07653 Variant SH3 domain
Function	Acts as an adapter protein of the FYN and LCP2 signaling cascades in T-cells. Modulates the expression of interleukin-2 (IL-2). Involved in platelet activation. Prevents the degradation of SKAP1 and SKAP2. May play a role in linking T-cell signaling to remodeling of the actin cytoskeleton.

> Gene Ontology [ TOP ]
Biological Process	GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006606 protein import into nucleus GO:0006607 NLS-bearing protein import into nucleus GO:0006913 nucleocytoplasmic transport GO:0007009 plasma membrane organization GO:0017038 protein import GO:0034504 protein localization to nucleus GO:0044744 protein targeting to nucleus GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0051169 nuclear transport GO:0051170 nuclear import GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:1902593 single-organism nuclear import GO:1990778 protein localization to cell periphery
Molecular Function	-
Cellular Component	GO:0015629 actin cytoskeleton

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1500931: Cell-Cell communication R-HSA-202433: Generation of second messenger molecules R-HSA-168256: Immune System R-HSA-391160: Signal regulatory protein (SIRP) family interactions R-HSA-202403: TCR signaling

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FYB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FYB and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25851535	Melanoma	Inhibit immunity (T cell function)	Together, we propose that targeting the unrecognized ADAP-SKAP55-NFATc1-PD-1 pathway might increase efficacy of anti-tumor immunotherapy.

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FYB in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FYB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.18	0.704
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.938	0.525
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.388	0.769
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.171	0.713
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.143	0.941
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.577	0.83
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.526	0.347
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.803	0.627
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.217	0.906
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.269	0.325
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.558	0.435
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.156	0.434

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FYB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	11.8	-11.8	0.193
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FYB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FYB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FYB. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FYB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FYB expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FYB and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FYB
Name	FYN binding protein
Aliases	SLAP-130; FYB-120/130; FYN-binding protein (FYB-120/130); ADAP; PRO0823; SLAP130; FYN-T-binding protein; SLP ......
Chromosomal Location	5p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FYB collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FYB